Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell …

clear cell carcinoma
clear cell renal cell carcinoma
carcinoma
primary cancer
metastatic cancer
  • 208 views
  • 22 Dec, 2020
  • 1 location
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

).), with or without s.c. aldesleukin (IL-2)). Patients diagnosed after the closure of R3 randomization will not be R4 randomized. For these patients the use of ch14.18/CHO antibody is recommended without

monoclonal antibody ch14.18
etoposide
busulfan
isotretinoin
topotecan
  • 308 views
  • 26 Jan, 2021
  • 126 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

etoposide
vincristine
busulfan
iobenguane
stem cell transplantation
  • 117 views
  • 01 Mar, 2022
  • 102 locations
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body

glomerular filtration rate
cancer
serum bilirubin
pet scan
monoclonal antibodies
  • 21 views
  • 13 Apr, 2022
  • 1 location
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

To evaluate safety, tolerance and efficacy of TASO(TGF-2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid

  • 0 views
  • 07 May, 2021
  • 1 location
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Background Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma

  • 0 views
  • 13 May, 2022
  • 1 location
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)

  • 0 views
  • 01 May, 2022
  • 2 locations
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Participants will include

biliary cancer
carcinoma
platelet count
metastatic biliary tract carcinoma
neutrophil count
  • 28 views
  • 07 Apr, 2022
  • 1 location
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with

squamous cell carcinoma
cellular therapy
platelet count
neutrophil count
hepatitis b antigen
  • 12 views
  • 06 May, 2022
  • 1 location
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

This is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with

clinical protocols
metastatic uveal melanoma
gilbert's syndrome
alopecia
neutrophil count
  • 30 views
  • 11 May, 2022
  • 1 location